Zhitong Financial APP News, Hanyu Pharmaceutical (300199.SZ) issued an announcement that the company recently learned through the official website of the Brazilian Health Supervision Agency (ANVISA) that VOL Pharma, the company's agent seller of terlivasopressin preparations for injection, had obtained approval for the product to be listed in Brazil.

It is reported that terlivasopressin is a synthetic vasopressin analogue, which is a vasoconstrictor in vasoactive drugs, which is mainly used to stop bleeding from varicose veins in liver cirrhosis. Now it is widely used in the treatment of hepatorenal syndrome, cirrhotic ascites, septic shock, burn, acute liver failure, cardiac arrest and so on.